|
Sign In to gain access to subscriptions and/or personal tools.
|
Paradoxical decrease in high density lipoprotein-cholesterol associated with statin and fenofibrate combination therapy
Jennifer Glaysher
Deparment of Clinical Biochemistry, Aintree Hospitals NHS Trust, Liverpool, UK
Charles Van Heyningen
Deparment of Clinical Biochemistry, Aintree Hospitals NHS Trust, Liverpool, UK, charles.vanheyningen{at}aintree.nhs.uk
References
- Sviridov D., Nestel P. Genetic factors affecting HDL levels, structure, metabolism and function. Curr Opin Lipidol 2007;18:157-63.[Web of Science][Medline]
[Order article via Infotrieve]
- Lan D., Silver D. Fenofibrate induces a novel degradation pathway for scavenger receptor B-I independent of PDZK1. J Biol Chem 2005;280:23390-6.[Abstract/Free Full Text]
- Nissen S., Nicholls S., Wolski K. et al. Effect of a potent and selective PPAR·agonist in patients with atherogenic dyslipidaemia or hypercholesterolaemia. Two randomised controlled trials. JAMA 2007;297:1362-73.[Abstract/Free Full Text]
- Hiukka A., Leinonen E., Jauhainen M. et al. Long-term effects of fenofibrate on VLDL and HDL subspecies in participants with type 2 diabetes mellitus. Diabetologia 2007;EPub ahead of print
- Ribas V., Palomer X., Roglans N. et al. Paradoxical exacerbation of combined hyperlipidaemia in human apolipoprotein A-II transgenic mice treated with fenofibrate. Biochimica et Biophysica Acta 2005;1737:130-7[Medline]
[Order article via Infotrieve]
- Gilde A., Fruchart JC, Staels B. Peroxisome proliferator-activated receptors at the crossroads of obesity, diabetes, and cardiovascular disease. JACC 2006;48(suppl):A24-A32.[Abstract/Free Full Text]
- Tai E.M., Collins D., Robins S. et al. The L162V polymorphism at the peroxisome proliferator activated receptor alpha locus modulates the risk of cardiovascular events associated with insulin resistance and diabetes mellitus: The Veterans Affairs HDL Intervention Trials (VA-HIT). Atherosclerosis 2006;187:153-60.[CrossRef][Medline]
[Order article via Infotrieve]
- Olukoga A. Paradoxical severe decrease in serum HDL-cholesterol after treatment with a fibrate. J Clin Pathol 2002;55:718.[Free Full Text]
- Gutschi L., Malcolm J., Favreau C., Ooi T. Paradoxically decreased HDL-cholesterol levels associated with rosiglitazone therapy. Ann Pharmacother 2006;40:1672-6.[Abstract/Free Full Text]
- Collinson PO, Hjelm CJ, Canep-Anson R. Paradoxical high-density lipoprotein reduction induced by fenofibrate and ciprofibrate. Ann Clin Biochem 1996;33:159-61.[Web of Science][Medline]
[Order article via Infotrieve]
- Oleesky D., Mir M. Paradoxical high-density lipoprotein reduction induced by fibrate therapy. Ann Clin Biochem 1997:34:573-4.[Web of Science][Medline]
[Order article via Infotrieve]
- Chandler HA, Batchelor AJ Ciprofibate and lipid profile. Lancet 1994;344:128-9.[Web of Science][Medline]
[Order article via Infotrieve]
- McLeod AJ, Warren RJ, Armitage M. Ciprofibrate and lipid profile. Lancet 1994;344;955.[Web of Science][Medline]
[Order article via Infotrieve]
- Capps NE Lipid profiles on fibric-acid derivatives. Lancet 1994;344;684-5.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Shetty C., Balasubramani M., Capps N. et al. Paradoxical HDL-C reduction during rosiglitazone and fibrate treatment. Diabet med 2007;24:94-7.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Murali M., Kratz A., Finberg K. Case 40-2006: A 64 year old man with anaemia and a low level of HDL-cholesterol. N Engl J Med 2006;355:2772-9.[Free Full Text]
- Normen L., Frohlich J., Montaner J. et al. Combination therapy with fenofibrate and rosiglitazone paradoxically lowers serum HDL cholesterol. Diabetes Care 2004;27:2241-2.[Free Full Text]
- McLeod AJ, Warren RJ, Armitage M. Abnormal lipid profiles on fibrate derivatives. Lancet 1996;347:261.[Web of Science][Medline]
[Order article via Infotrieve]
- Crook M.A., Lynas J., Wray R. A paradoxical severe decrease in serum HDL-cholesterol after treatment with a fibrate. J Clin Pathol 2000;53:796-7.[Abstract/Free Full Text]
- Seber S., Ucak S., Basat O., Altuntas Y. The effect of dual PPAR-
 / stimulation with combination of rosiglitazone and fenofibrate on metabolic parameters in type 2 diabetic patients. Diabetes Res Clin Pract 2006;71:52-8.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
The British Journal of Diabetes & Vascular Disease, Vol. 7, No. 6,
295-297 (2007)
DOI: 10.1177/14746514070070060701
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
D. Mymin, T. Dembinski, and M. H. Friesen
Iatrogenic Severe Depression of High-Density Lipoprotein Cholesterol
J. Clin. Pharmacol.,
July 1, 2009;
49(7):
865 - 871.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G Magee and P C Sharpe
Paradoxical decreases in high-density lipoprotein cholesterol with fenofibrate: a quite common phenomenon
J. Clin. Pathol.,
March 1, 2009;
62(3):
250 - 253.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Hulme, S. O'Brien, J. Cardwell, S. McNulty, and K. Hardy
Paradoxical decrease in high-density lipoprotein-cholesterol associated with statin-fenofibrate combination therapy
The British Journal of Diabetes & Vascular Disease,
January 1, 2008;
8(1):
5 - 5.
[PDF]
|
|
|
|
|
